🇺🇸 FDA
Patent

US 12178887

NIR-conjugated tumor-specific antibodies and uses thereof

granted A61KA61K2039/505A61K49/0002

Quick answer

US patent 12178887 (NIR-conjugated tumor-specific antibodies and uses thereof) held by The Regents of the University of California expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K49/0002, A61K49/0032, A61K49/0058